KALA Stock Forecast: Kala Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.71

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 15 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.7M
Ticker Nerd rank
15/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$1.7M
Net income−$1.6M
Free cash flow−$1.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Kala Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
15/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
71
Issuance
51
Accruals
38
Revisions
20
Quality
13
Volatility
8
Momentum
4
Value
2

Growth (71): Sales and profits are climbing, and climbing faster than before.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KALA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KALA, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Sept 2025HC Wainwright & Co.DowngradeNeutral—
17 Sept 2025HC Wainwright & Co.MaintainsBuy—
11 Sept 2025OppenheimerMaintainsOutperform—
8 Sept 2025MizuhoInitiatesOutperform—
11 July 2025Ladenburg ThalmannInitiatesBuy—
2 June 2025OppenheimerAssumesOutperform$15
23 May 2025HC Wainwright & Co.MaintainsBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
13 Feb 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
19 Aug 2024OppenheimerReiteratesOutperform—
17 May 2024HC Wainwright & Co.MaintainsBuy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
1 Apr 2024OppenheimerReiteratesOutperform—
17 Nov 2023HC Wainwright & Co.MaintainsBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
10 May 2023HC Wainwright & Co.ReiteratesBuy—
1 May 2023HC Wainwright & Co.ReiteratesBuy—
12 Apr 2023HC Wainwright & Co.MaintainsBuy—
27 Mar 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KALA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

KALA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.2×

Cheaper than 94% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−345.3%

Higher than 4% of US stocks

Return on assets
−65.4%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kala Bio, Inc. has a market value of $1.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$10.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.9M.

  • Shares outstanding: 19.3M.

  • Kala Bio, Inc. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

KALA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KALAKala Bio, Inc.$1.7M15
PPCBPropanc Biopharma, Inc.$1.8M45
CLDICalidi Biotherapeutics, Inc.$1.6M20
EOCNEocene Ltd.$1.9M11
JUNSJupiter Neurosciences, Inc.$1.6M14
XRTXXORTX Therapeutics, Inc.$1.9M11
ENLVEnlivex Ltd.$1.6M4

Take a look at KALA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Kala Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KALA

How does Ticker Nerd's model rank KALA?

As at 21 Nov 2026, Kala Bio, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (71 of 100).

What is the KALA stock forecast for 2030?

No analyst covering Kala Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KALA are extrapolating price history, which says nothing about the business.

What does Kala Bio, Inc. do?

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe diseases affecting the front and back of the eye. Its primary development focus is KPI-012, an investigational biologic based on a mesenchymal stem cell secretome platform and designed to address persistent corneal epithelial defects, a condition involving impaired corneal healing.

Company

About Kala Bio, Inc.

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe diseases affecting the front and back of the eye. Its primary development focus is KPI-012, an investigational biologic based on a mesenchymal stem cell secretome platform and designed to address persistent corneal epithelial defects, a condition involving impaired corneal healing. The company’s activities center on ophthalmic research, clinical development, regulatory work, and potential commercialization of specialized treatments for patients with limited therapeutic options. KALA BIO, Inc. operates within the biotechnology and pharmaceutical sectors, with particular relevance to regenerative medicine, ocular surface disease, and rare-disease therapeutics. Its business model is centered on advancing proprietary product candidates through clinical development and establishing a specialized pipeline in ophthalmology. The company’s role in the financial market reflects the characteristics of a development-stage life sciences business, where value is closely connected to scientific research, clinical programs, intellectual property, and regulatory progress.

CEO Mr. Avi Minkowitz · 6 employees · United States · https://www.kalarx.com